ConductScience.org, home

Paper34849495

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era.

Fan H and 4 others. Lancet Microbe, 2022. Cited by 40 papers, by iCite.

Cite this record

ConductScience Library. The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era. Papers, record 34849495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34849495

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era.
PubMed
Journal
Lancet Microbe
PubMed
Year
2022
PubMed
Publication types
Letter, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
2.17
iCite
Revised in PubMed
2022-05-02
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fan HHuahao
2Lou FFuxing
3Fan JJunfen
4Li MMaochen
5Tong YYigang

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
VaccinesMajor topic
Humans
SARS-CoV-2

References4

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132253226An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.Sci Transl Med2020https://conductscience.org/library/papers/32253226PubMed
233961695β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.J Infect Dis2021https://conductscience.org/library/papers/33961695PubMed
334310217Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/34310217PubMed
434518697Molnupiravir: coding for catastrophe.Nat Struct Mol Biol2021https://conductscience.org/library/papers/34518697PubMed

Download CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
38915977Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study.Cureus2024https://conductscience.org/library/papers/38915977PubMed
38361624Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens.iScience2024https://conductscience.org/library/papers/38361624PubMed
37841365Taking stock of the mutations in human SARS-CoV-2 spike proteins: From early days to nearly the end of COVID-19 pandemic.Curr Res Struct Biol2023https://conductscience.org/library/papers/37841365PubMed
37542245Metallic nanoplatforms for COVID-19 diagnostics: versatile applications in the pandemic and post-pandemic era.J Nanobiotechnology2023https://conductscience.org/library/papers/37542245PubMed
37041762COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies.MedComm (2020)2023https://conductscience.org/library/papers/37041762PubMed
37020822The shift of percent excess mortality from zero-COVID policy to living-with-COVID policy in Singapore, South Korea, Australia, New Zealand and Hong Kong SAR.Front Public Health2023https://conductscience.org/library/papers/37020822PubMed
36770656Coronavirus Inhibitors Targeting nsp16.Molecules2023https://conductscience.org/library/papers/36770656PubMed
36698809
Luteolin-rich fraction from Perilla frutescens seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID.
Front Med (Lausanne)2022https://conductscience.org/library/papers/36698809PubMed
36560775The Effect of Preventive Measures and Vaccination against SARS-CoV-2 on the Infection Risk, Treatment, and Hospitalization: A Cross-Sectional Study of Algeria.Viruses2022https://conductscience.org/library/papers/36560775PubMed
36105233Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route.Front Pharmacol2022https://conductscience.org/library/papers/36105233PubMed
35992968Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention.MedComm (2020)2022https://conductscience.org/library/papers/35992968PubMed
35862736Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.Clin Microbiol Rev2022https://conductscience.org/library/papers/35862736PubMed
35807916
Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway.
Nutrients2022https://conductscience.org/library/papers/35807916PubMed
35779085Pandemic COVID-19, an update of current status and new therapeutic strategies.Naunyn Schmiedebergs Arch Pharmacol2022https://conductscience.org/library/papers/35779085PubMed
35726542OMICRON: Virology, immunopathogenesis, and laboratory diagnosis.J Gene Med2022https://conductscience.org/library/papers/35726542PubMed
35711421Overview of Breastfeeding Under COVID-19 Pandemic.Front Immunol2022https://conductscience.org/library/papers/35711421PubMed
35663284Fluorine in Medicinal Chemistry: In Perspective to COVID-19.ACS Omega2022https://conductscience.org/library/papers/35663284PubMed
35504917COVID-19 vaccine development: milestones, lessons and prospects.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35504917PubMed
35489042Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy.ChemMedChem2022https://conductscience.org/library/papers/35489042PubMed
35444647Molnupiravir and Its Antiviral Activity Against COVID-19.Front Immunol2022https://conductscience.org/library/papers/35444647PubMed

See all 28 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACE259272PubTator's text mininghttps://conductscience.org/library/genes/59272NCBI Gene
TMPRSS27113PubTator's text mininghttps://conductscience.org/library/genes/7113NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34849495

GET https://conductscience.org/api/papers/v1/34849495/cited_by?page=2